Novo Nordisk A/S
(NYSE : NVO)

( )
NVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.03%178.810.7%$1159.32m
LLYEli Lilly & Co. -0.59%368.231.1%$1130.48m
MRKMerck & Co., Inc. -0.54%109.240.7%$1027.68m
PFEPfizer Inc. -0.25%51.010.9%$989.28m
ABBVAbbVie, Inc. -0.03%161.581.9%$866.05m
BMYBristol-Myers Squibb Co. 0.30%81.111.1%$773.98m
AZNAstraZeneca Plc 0.00%68.341.0%$358.11m
HZNPHorizon Therapeutics Plc 3.09%104.005.4%$318.77m
IDXXIDEXX Laboratories, Inc. 0.00%439.173.9%$229.98m
CTLTCatalent, Inc. 0.02%52.241.9%$213.67m
GSKGSK Plc 0.21%35.110.3%$190.15m
NVSNovartis AG -0.21%89.620.2%$185.93m
NVONovo Nordisk A/S 0.00%126.130.1%$172.82m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%220.258.0%$161.43m
RGENRepligen Corp. 0.00%188.176.7%$134.32m

Company Profile

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.